Melbourne, Australia; Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 June 2015.

The cash balance as at 30 June 2015 was $30.8 million, with the operating and investing cash flows for the full year of $14.3 million.

In addition to internal operating costs, external expenditures for the quarter include costs related to both the DEP™ docetaxel phase 1 trial and the phase 3 clinical trials for VivaGel^® to prevent recurrent bacterial vaginosis (BV).  Both clinical programs are progressing well, with activities now underway in preparation for a subsequent phase 2 DEP^TM docetaxel clinical trial.  In the current study, DEP™ docetaxel continues to exhibit a complete lack of neutropenia and hair loss at dose levels comparable to and above the most commonly used doses of Taxotere^®.

A highlight in the quarter was the signing of an extension to the existing drug delivery collaboration agreement with AstraZeneca to develop a novel oncology drug using Starpharma’s DEP™ technology.  This agreement follows extensive testing of DEP™ versions of the oncology drug.  Based on the successful results of this testing, AstraZeneca is now conducting further pre-clinical studies with a view to subsequent commencement of clinical trials, if results continue to be positive.

The quarter has also seen excellent progress of regulatory submissions for VivaGel^® for symptomatic relief of BV lodged in the first calendar quarter.  Recruitment also continues across the US, Canada, Europe, Asia and Mexico in the two phase 3 clinical trials for VivaGel^® to prevent recurrent BV.

Starpharma also expects new retail channels to be added in the near future for the VivaGel^® condom marketed in Australia under Ansell’s LifeStyles^® Dual Protect™ brand.

“This quarter - and indeed the year - has been another period of significant progress for Starpharma.  The extension of our agreement with AstraZeneca is solid endorsement of our DEP™ drug delivery technology and we look forward to working closely with them through the next stage of the program,” said Starpharma CEO, Dr Jackie Fairley.

“This high level of activity in our partnered drug programs, coupled with two exciting clinical programs, a product in market and regulatory reviews well advanced for others, and a robust cash position, allows us to confidently and intently advance our entire portfolio of VivaGel^®, drug delivery and agrochemicals commercialisation projects.”

Download ASX Announcement: Appendix 4C - Quarterly Cashflow Report (pdf file, 131kb)